ACROBioSystems and Diagnostic Biochips have partnered to accelerate neuroscience drug discovery, according to a recent announcement. ACROBioSystems has launched in vivo electrophysiology solutions for neuroscience research under its Aneuro brand that will work without a headstage, reducing the physical burden on animal heads without compromising signal channels. The probes are designed to help researchers monitor the brain's field potential and electrical signals at the neuron level across different brain regions to provide critical information about neural network function and the biological pathway behind neurological disease pathology. Data acquisition systems along with AI/cloud-based data analysis software are also available to drive structural and functional analysis of neural circuits, electrophysiological biomarker discovery, and drug screening. Under Aneuro, all in vivo electrophysiology alongside other neurological drug-development products including pre-formed fibrils (PFFs), Tau, and many other protein antigens associated with neurological diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, brain tumors and other neurological related diseases.
Keywords: ACROBioSystems, Diagnostic Biochips, neuroscience drug discovery, in vivo electrophysiology solutions, Aneuro brand
ACROBioSystems has partnered with Diagnostic Biochips to launch in